I am founder of the Cancer Innovation and Regulation Initiative at Harvard Medical School/Mass General Brigham and serve on the European Society for Medical Oncology (ESMO) Clinical Benefit Scale Committee. I am also a Visiting Senior Fellow at the London School of Economics (2026-2027). Previously, I was a Visiting Expert at the European Medicines Agency and a member of a US Food and Drug Administration working group on molecular targets for pediatric cancers.
My work focuses on new medicines and digital health in the US and Europe. I have published over 100 peer-reviewed papers, including in Science, JAMA, and the New England Journal of Medicine. I received my undergraduate and medical degrees (summa cum laude) from Harvard. In 2023, I was selected as a STAT “Wunderkind,” as one of the nation’s leading experts on pharmaceutical regulation.